Syros Pharmaceuticals, Inc. (SYRS) Operating Income (Loss) USD 2015 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Syros Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2015 to 2024.
  • Syros Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$30.9 M, a 6.9% increase year-over-year.
  • Syros Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$127 M, a 11% increase year-over-year.
  • Syros Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$129 M, a 5.07% increase from 2022.
  • Syros Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$136 M, a 36.7% decline from 2021.
  • Syros Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$99.4 M, a 20.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$127 M -$30.9 M +$2.29 M +6.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$129 M -$27.1 M +$8.86 M +24.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-27
Q3 2023 -$138 M -$34.6 M +$4.82 M +12.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$143 M -$34 M -$231 K -0.68% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 -$142 M -$33.2 M -$6.56 M -24.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$136 M -$36 M -$10.6 M -41.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-27
Q3 2022 -$125 M -$39.5 M -$12.5 M -46.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$113 M -$33.8 M -$7.63 M -29.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$105 M -$26.7 M -$5.71 M -27.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$99.4 M -$25.4 M +$3.8 M +13% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-02
Q3 2021 -$103 M -$26.9 M -$7.91 M -41.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$95.3 M -$26.1 M -$9.4 M -56.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$85.9 M -$20.9 M -$3.6 M -20.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$82.3 M -$29.2 M -$9.05 M -44.9% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-04
Q3 2020 -$73.2 M -$19 M +$1.39 M +6.83% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 -$74.6 M -$16.7 M +$3.47 M +17.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$78.1 M -$17.3 M -$366 K -2.16% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$77.7 M -$20.2 M -$1.56 M -8.41% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-04
Q3 2019 -$76.2 M -$20.4 M -$4.07 M -24.9% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-04
Q2 2019 -$72.1 M -$20.2 M -$5.66 M -38.9% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-04
Q1 2019 -$66.4 M -$17 M -$2.15 M -14.5% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-04
Q4 2018 -$64.3 M -$18.6 M -$3.09 M -19.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-05
Q3 2018 -$61.2 M -$16.3 M -$2.28 M -16.2% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-05
Q2 2018 -$58.9 M -$14.5 M -$1.04 M -7.66% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-05
Q1 2018 -$57.9 M -$14.8 M -$3.21 M -27.6% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-05
Q4 2017 -$54.7 M -$15.5 M -$4.48 M -40.5% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 -$50.2 M -$14 M +$177 K +1.25% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-07
Q2 2017 -$50.4 M -$13.5 M -$1.45 M -12% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-07
Q1 2017 -$48.9 M -$11.6 M -$977 K -9.19% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-07
Q4 2016 -$48 M -$11 M -$356 K -3.33% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-12
Q3 2016 -$47.6 M -$14.2 M -$5.75 M -68% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-12
Q2 2016 -$41.9 M -$12.1 M -$5.97 M -97.9% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-12
Q1 2016 -$35.9 M -$10.6 M -$6.06 M -133% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-12
Q4 2015 -$29.8 M -$10.7 M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-20
Q3 2015 -$8.46 M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-20
Q2 2015 -$6.1 M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-20
Q1 2015 -$4.57 M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.